VEGFA and colorectal carcinoma: Combination regimes of chemotherapeutic agents and targeted therapies (e.g., vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor inhibitors) benefit some patients (Martins et al., 2018), however the 5-year relative survival rate for metastatic CRC remains poor at 14%.